November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Deniz Can Guven: The OS benefits of cancer drugs approved by surrogate endpoints
Jun 24, 2024, 03:22

Deniz Can Guven: The OS benefits of cancer drugs approved by surrogate endpoints

Deniz Can Guven, The Editorial Board Member in BMC Cancer, shared on X:

“Out in The Lancet Oncology in OA. The OS benefits of cancer drugs approved by surrogate endpoints.

  • 38 indications with OS data after approval
  • Significant OS benefit in only 32% of the indications
  • Late availability of (>3 years) non-significant OS results

The value of surrogate endpoints in approvals. A double-edged sword.”

Deniz Can Guven

Source: Deniz Can Guven/X